Literature DB >> 18981630

Salivary chromogranin A: useful and quantitative biochemical marker of affective state in patients with amyotrophic lateral sclerosis.

Konen Obayashi1, Kimiko Sato, Rie Shimazaki, Tomoko Ishikawa, Katsumasa Goto, Hidetsugu Ueyama, Teruaki Mori, Yukio Ando, Toshihide Kumamoto.   

Abstract

OBJECTIVE: To evaluate the affective state biochemically and quantitatively in amyotrophic lateral sclerosis (ALS) patients using salivary chromogranin A (CgA) measurement. SUBJECTS AND METHODS: Twelve moderate and 12 terminal ALS patients defined using the ALS Health State Scale were studied. The correlation between salivary CgA levels and the 40-item ALS assessment questionnaire (ALSAQ-40) scores was investigated in 12 moderate ALS patients. Moreover, salivary CgA levels in 12 terminal ALS patients, in whom the emotional functioning score could not be assessed, were compared with those in 12 moderate ALS patients, 7 patients with tube-fed vascular dementia, and in 26 healthy volunteers.
RESULTS: There were individual differences in salivary CgA levels in spite of similar severity of disease; however, mean salivary CgA levels in terminal ALS patients, in whom the emotional functioning score based on interview could not be assessed, was significantly higher (12.58+/-2.79 pmol/mL) than in patients with moderate ALS (6.36+/-1.62 pmol/mL, p<0.05), tube-fed vascular dementia (4.04+/-2.04 pmol/mL, p<0.01), and healthy volunteers (3.77+/-1.90 pmol/mL, p<0.01). Moreover, a statistically significant positive correlation was observed between salivary CgA levels and emotional functioning scores on ALSAQ-40 in moderate patients (r=0.892, p<0.01).
CONCLUSION: Salivary CgA may be a useful and quantitative biochemical marker of the affective state, not only in moderate, but also in terminal ALS. Periodic salivary CgA measurements over the long term and/or in various situations could have therapeutic implications for the quality of life of these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981630     DOI: 10.2169/internalmedicine.47.1278

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  7 in total

Review 1.  The extended granin family: structure, function, and biomedical implications.

Authors:  Alessandro Bartolomucci; Roberta Possenti; Sushil K Mahata; Reiner Fischer-Colbrie; Y Peng Loh; Stephen R J Salton
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

Review 2.  Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis.

Authors:  Lucas T Vu; Robert Bowser
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

3.  Chromogranin B P413L variant as risk factor and modifier of disease onset for amyotrophic lateral sclerosis.

Authors:  Francois Gros-Louis; Peter M Andersen; Nicolas Dupre; Makoto Urushitani; Patrick Dion; Frederique Souchon; Monique D'Amour; William Camu; Vincent Meininger; Jean-Pierre Bouchard; Guy A Rouleau; Jean-Pierre Julien
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-09       Impact factor: 11.205

Review 4.  Amyotrophic lateral sclerosis: a focus on disease progression.

Authors:  Ana C Calvo; Raquel Manzano; Deise M F Mendonça; María J Muñoz; Pilar Zaragoza; Rosario Osta
Journal:  Biomed Res Int       Date:  2014-08-03       Impact factor: 3.411

5.  Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis.

Authors:  C Carlomagno; P I Banfi; A Gualerzi; S Picciolini; E Volpato; M Meloni; A Lax; E Colombo; N Ticozzi; F Verde; V Silani; M Bedoni
Journal:  Sci Rep       Date:  2020-06-23       Impact factor: 4.379

Review 6.  Salivary Biomarkers: Future Approaches for Early Diagnosis of Neurodegenerative Diseases.

Authors:  Giovanni Schepici; Serena Silvestro; Oriana Trubiani; Placido Bramanti; Emanuela Mazzon
Journal:  Brain Sci       Date:  2020-04-21

Review 7.  Salivary biomarkers for the diagnosis and monitoring of neurological diseases.

Authors:  Raymond Farah; Hayat Haraty; Ziad Salame; Youssef Fares; David M Ojcius; Najwane Said Sadier
Journal:  Biomed J       Date:  2018-05-10       Impact factor: 4.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.